Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults

NCT02562482 is registered in ClinicalTrials.gov with National Institute of Allergy and Infectious Diseases (NIAID) as lead sponsor.

NCT NCT02562482
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02562482 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Phase
Phase 2
Overall status
Completed
Start date
November 18, 2015
Completion date
March 6, 2018
Enrollment
400 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chikungunya virus infection